Figure 3.
Trametinib with pazopanib reduces ERK and AKT activation in vivo. Established 8505C and CAL62 xenograft tumors treated with the indicated drugs for 2–3 weeks were harvested 4 h after dosing. Immunohistochemistry for pERKT202/Y204 and pAKTS473 was performed on formalin-fixed, paraffin-embedded sections. ERK activation was significantly inhibited by trametinib or trametinib plus pazopanib but not by single agent pazopanib. (Scale bar, 20 µm; DAB used as chromogen).